A Study of LY4088044 in Healthy Participants
Start Date
7/24/2025
Completion Date
7/1/2027
Summary
The purpose of this study is to evaluate how well LY4088044 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4088044 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 92 weeks for Parts A, B, and C, excluding screening.
Eligibility Criteria
Age Range: 18 years to 65 years
Interventions
LY4088044
LY4088044
Placebo
Placebo
Conditions
Locations
Collaborative Neuroscience Network - CNS
Los Alamitos, California 90720
United States
ICON
Lenexa, Kansas 66219
United States
ICON Early Phase Services
San Antonio, Texas 78232
United States
ICON
Salt Lake City, Utah 84124
United States
New Zealand Clinical Research Christchurch
Christchurch, 8011
New Zealand
Lilly Centre for Clinical Pharmacology
Singapore, 138623
Singapore